Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72s (DRL-72s) schedule in rats: involvement of the serotonergic receptors in restoring the deficits

Eur J Pharmacol. 2013 Nov 15;720(1-3):344-54. doi: 10.1016/j.ejphar.2013.10.005. Epub 2013 Oct 14.

Abstract

Scopolamine, a non-selective muscarinic receptor antagonist has widespread central nervous system effects. Muscarinic receptors located in the central nervous system play a vital role in the modulation of impulsivity. The objective of the current study was to evaluate the effect of scopolamine on impulsivity using differential-reinforcement-of-low-rate 72-s schedule (DRL-72s) and to demonstrate the involvement of serotonergic receptors in mediating the effect of olanzapine (atypical antipsychotic) on scopolamine induced impulsivity. Scopolamine impaired the performance of the rats trained under DRL-72s schedule. Olanzapine reversed the deficits induced by scopolamine. We evaluated the effect of donepezil (cholinesterase inhibitor), SB-742457 (5-HT6 and 5-HT2a antagonist), and haloperidol (typical antipsychotic) in rats challenged with scopolamine in the DRL-72s schedule to identify the receptor(s) involved in reversing the deficits. SB-742457 partially reversed the deficits, but donepezil and haloperidol did not show any effects on the deficits induced by scopolamine. Olanzapine and SB-742457 shifted the peak location (PkL) towards longer IRT duration, indicating a decrease in motor impulsivity. Modulation of scopolamine-induced impulsivity by olanzapine could be partly due to its antagonistic action at 5-HT2a and 5-HT6 receptors, respectively. Superior effects of olanzapine on impulsivity in schizophrenic patients may be mediated through the antagonism of 5-HT2a and 5-HT6 receptors.

Keywords: DRL-72s; Donepezil; Haloperidol; Impulsivity; Olanzapine; SB-742457; Scopolamine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Behavior, Animal / drug effects
  • Benzodiazepines / pharmacology*
  • Benzodiazepines / therapeutic use
  • Cholinesterase Inhibitors / pharmacology
  • Conditioning, Operant
  • Donepezil
  • Haloperidol / pharmacology
  • Impulsive Behavior / chemically induced
  • Impulsive Behavior / drug therapy
  • Impulsive Behavior / physiopathology
  • Indans / pharmacology
  • Male
  • Muscarinic Antagonists
  • Olanzapine
  • Piperidines / pharmacology
  • Quinolines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Serotonin
  • Reinforcement, Psychology
  • Scopolamine
  • Serotonin Antagonists / pharmacology*
  • Serotonin Antagonists / therapeutic use
  • Sulfones / pharmacology

Substances

  • 3-benzenesulfonyl-8-piperazin-1-ylquinoline
  • Antipsychotic Agents
  • Cholinesterase Inhibitors
  • Indans
  • Muscarinic Antagonists
  • Piperidines
  • Quinolines
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Serotonin
  • Serotonin Antagonists
  • Sulfones
  • serotonin 6 receptor
  • Benzodiazepines
  • Donepezil
  • Scopolamine
  • Haloperidol
  • Olanzapine